Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
An RX mirror and its underlying label are not independent clinical confirmations.
Check source scope before reading a dose
LITFULO: selected primary-label renal guidance and limits
Product / population
LITFULO oral capsules for labeled severe alopecia areata in adults and adolescents >=12 years; PK-only renal summary.
Renal method
MDRD eGFR, mL/min as printed in PK text
Source revision
Revision date not captured in selected review; retrieval date is not revision date.
Retrieved
2026-11-07
Local review status
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
LITFULO: source applicability and renal evidence limits
ESRD and renal-transplant recipients not studied. The RX mirror is not independent corroboration of the matched label.
What to reconcile: Do not turn a PK observation into a dialysis or transplant regimen.
DailyMed / product prescribing information · LITFULO oral capsules for labeled severe alopecia areata in adults and adolescents >=12 years; PK-only renal summary.
Renal method: MDRD eGFR, mL/min as printed in PK text Source date: Revision date not captured in selected review; retrieval date is not revision date. Retrieved: 2026-11-07
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
Before using this finding
ESRD and renal-transplant recipients not studied.
Dialysis evidence: No dialysis regimen established in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Section 12.3, Patients with Renal Impairment
Severe impairment (eGFR <30) increased AUC by 55.2%; the label considers this difference not clinically significant. Mild/moderate impairment was not studied because a clinically relevant exposure increase was not expected. ESRD and renal-transplant recipients were not studied. These PK findings are not a validated ESRD or transplant dosing regimen.
RDM72-ritlecitinib-litfulo-label-1 · Source locator: Section 12.3, Patients with Renal Impairment
Source-specific limits
Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
